What motivates Parkinson's disease patients to enter clinical trials?

Parkinsonism and Related Disorders

Volumn 17, Issue 9, 2011, Pages 667-671

  Valadas, Anabela ^a,b   Coelho, Miguel ^a,b   Mestre, Tiago ^b   Guedes, Leonor Correia ^a,b   Finisterra, Maria ^b   Noronha, Ana ^b   Rosa, Mário M ^a,b   Sampaio, Cristina ^b   Ferreira, Joaquim J ^a,b  

^a HOSPITAL DE SANTA MARIA   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

Author keywords

Clinical trial; Informed consent; Parkinson's disease; Placebo effect; Recruitment

Indexed keywords

AGED; ARTICLE; CLINICAL TRIAL (TOPIC); CONCEPT FORMATION; CROSS SECTIONAL STUDY; DECISION MAKING; DISEASE DURATION; FEMALE; HEALTH CARE ACCESS; HUMAN; INFORMED CONSENT; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MOTIVATION; PARKINSON DISEASE; PATIENT PARTICIPATION; PATIENT SAFETY; PATIENT SATISFACTION; PLACEBO EFFECT; PRIORITY JOURNAL; QUESTIONNAIRE; STUDY DESIGN;

AGED; CLINICAL TRIALS AS TOPIC; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; INFORMED CONSENT; MALE; MOTIVATION; PARKINSON DISEASE; PATIENT SELECTION; QUESTIONNAIRES;

EID: 80054872611     PISSN: 13538020     EISSN: 18735126     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2011.05.023     Document Type: Article

References (23)

1. Tolosa E., Katzenschlager R. Pharmacological management of Parkinson's disease. Parkinson's disease and movement disorders 2007, p110-145. Lippincott Williams & Wilkins, Philadelphia. J. Jankovic, E. Tolosa (Eds.).
2. Goetz C.G., Koller W.C., Poewe W., Rascol O., Sampaio C. Management of Parkinson's disease: an evidence-based review. Movement Disorders 2002, 17(Suppl. 4):S1-S166.
3. Rascol O., Goetz C.G., Koller W., Poewe W., Sampaio C. Treatment interventions for Parkinson's disease: an evident-based assessment. Lancet 2002, 359:1589-1598.
4. Muenter M.D. Double-blind, placebo-controlled study of levodopa therapy in Parkinson's disease. Neurology 1970, 20(Suppl. 12):6-13.
5. Campbell M.K., Snowdon C., Francis D., Elbourne D., McDonald A.M., Knight R., et al. Recruitment to randomised trials: strategies for trial enrolment and participation study. The STEPS study. Health Technology Assessment 2007, 11(no.48). the STEPS group.
6. Almeida L., Kashdan T.B., Coelho R., Albino-Teixeira A., Soares-da-Silva P. Healthy subjects volunteering for phase I studies: influence of curiosity, exploratory tendencies and perceived self-efficacy. International Journal of Clinical Pharmacology and Therapeutics 2008, 46(no. 3):p109-118.
7. Silverstein M.P., Jacobson C.E., Okun M.S., Rodriguez R.L., Fernandez Gainesville H.H. Clinical trial participation in movement disorders: why do patients accept or reject? Abstracts of the Movement Disorder Society's Eleventh International Congress of Parkinson's disease and Movement Disorders. Movement Disorders 2007, 24(Suppl. 16):S213.
8. Russell M.L., Moralejo D.G., Burgess E.D. Paying research subjects: participants' perspectives. Journal of Medical Ethics 2000, 26:126-130.
9. Robiner W.N. Enhancing adherence in clinical research. Contemporary Clinical Trials 2005, 26:59-77.
10. Ellis P.M. Attitudes towards and participation in randomised clinical trials in oncology: a review of the literature. Annals of Oncology 2000, 11:939-945.
11. Schaeffer M.H., Kratz D.S., Wichman A., Masur H., Reed E., Vinicky J.K. The impact of disease severity on the informed consent process in clinical research. The American Journal of Medicine 1996, 100:261-268.
12. Verheggen F.W.S.M., Nieman F., Jonkers R. Determinants of patient participation in clinical studies requiring informed consent: why patients enter a clinical trial. Patient Education and Counseling 1998, 35:111-125.
13. Davis T.C., Holcombe R.F., Berkel H.J., Pramanik S., Divres S.G. Informed consent for clinical trials: a comparative study of standard versus simplified forms. Journal of the National Cancer Institute 1998, 90(no. 9):668-674.
14. Edwards S.J.L., Lilford R.J., Hewison J. The ethics of randomised controlled trials from the perspectives of patients, the public and healthcare professionals. British Medical Journal 1998, 317:1209-1212.
15. Featherstone K., Donovan J.L. Random allocation or allocation at random? Patients' perspectives of participation in a randomised controlled trial. British Medical Journal 1998, 317:1177-1180.
16. Goetz C.G., Janko K., Blasucci L., Jaglin J.A. Impact of placebo assignment in clinical trials of Parkinson's disease. Movement Disorders 2003, 18(no. 10):1146-1149.
17. Goetz C.G., Leurgans S., Raman R., Stebbins G.T. Objectives changes in motor function during placebo treatment in PD. Neurology 2000, 54:710-714.
18. Shetty N., Friedman J.H., Kieburtz K., Marshall F.J., Oakes D. The placebo response in Parkinson's disease. Clinical Neuropharmacology 1999, 22(no. 4):207-212. the Parkinson's disease study group.
19. Goetz C.G., Leurgans S., Raman R. Placebo-associated improvements in motor function: comparison of subjective and objective sections of the UPDRS in early PD. Movement Disorders 2002, 17(2):283-288. Parkinson Study Group.
20. Welton A.J., Vickers M.R., Cooper J.A., Meade T.W., Marteau T.M. Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study. British Medical Journal 1999, 318:1114-1117.
21. Ross S., Grant A., Counsell C., Gillespie W., Russell I., Prescott R. Barriers to participation in randomised controlled trials: a systemic review. Journal of Clinical Epidemiology 1999, 52(12):1143-1156.
22. Almeida L., Azevedo B., Nunes T., Vaz-da-Silva M., Soares-da-Silva P. Why healthy subjects volunteer for phase I studies and how they perceive their participation?. European Journal of Clinical Pharmacology 2007, 63:1085-1094.
23. Davidson K.M., Espie C.J., Lammie C. Conducting randomised controlled trials: finding better ways to explain research to people with anti-social personality disorder who have low literacy levels. Criminal Behaviour and Mental Health 2011 Apr 4, [Epub ahead of print]. 10.1002/cbm.811.